Dr Peter M. George is a Consultant Respiratory Physician with a specialist interest in Interstitial Lung Disease at the Royal Brompton and Harefield NHS Foundation Trust. He is also an Honorary member of the Vascular Biology research group at the National Heart and Lung Institute.
Peter qualified from Imperial College School of Medicine in 2005. He intercalated with a BSc in Pharmacology and Toxicology (2003) and his research project was awarded first class honours. He undertook his junior doctor training in London, working at a number of academic institutions including St Mary's Hospital, the Hammersmith Hospital, the Royal Brompton Hospital and the Royal Marsden Hospital.
In 2008 he gained his membership of the Royal College of Physicians and in 2009 was appointed to the post of NIHR Academic Clinical Fellow in Respiratory Medicine at Imperial College.
Peter was then awarded a prestigious MRC Clinical Research Training Fellowship in 2011 and submitted his PhD in July 2014 under the supervision of Professor Jane Mitchell. His research focused on the relationship between innate immune dysregulation, namely interferon pathways, and pulmonary vascular inflammation. This work was referenced in the 2013 World Health Organisation international pulmonary hypertension guidelines as the first to describe a mechanism for interferon induced pulmonary arterial hypertension. Peter has published first author journal articles in the BMJ, New England Journal of Medicine, Lancet Respiratory Medicine and Circulation Research and has also published papers in the American Journal of Respiratory and Critical Care Medicine and Thorax.
Peter continues to be involved in clinical academia through his Consultant post at the Royal Brompton and his ongoing academic involvement at Imperial College. He remains an active member of the research group through the supervision of PhD students and ongoing applications for research funding.
et al., 2016, An emerging interstitial lung disease., Lancet Respiratory Medicine, Vol:4, ISSN:2213-2619, Pages:762-762
Garner J, George PM, Renzoni E, 2015, Cough in interstitial lung disease, Pulmonary Pharmacology & Therapeutics, Vol:35, ISSN:1094-5539, Pages:122-128
George PM, Wort SJ, Mitchell JA, 2014, Proteome-wide Analysis and CXCL4 in Systemic Sclerosis, New England Journal of Medicine, Vol:370, ISSN:0028-4793, Pages:1561-1562
George PM, Wort SJ, Mitchell JA, 2014, Use of interferon beta for acute respiratory distress syndrome: proceed with caution., The Lancet Respiratory Medicine, Vol:2
et al., 2014, Evidence for the Involvement of Type I Interferon in Pulmonary Arterial Hypertension, Circulation Research, Vol:114, ISSN:0009-7330, Pages:677-688
et al., 2012, Pharmacology and therapeutic potential of interferons., Pharmacol Ther. 2012 Jul;135(1):44-53
et al., 2012, A comparison between two strategies for monitoring hepatic function during antituberculous therapy, Am J Respir Crit Care Med, Vol:185, ISSN:1535-4970, Pages:653-659
et al., 2011, Improved Survival at Low Lung Function in Cystic Fibrosis; a cohort study from 1990 to 2007, Bmj 2011; 342:d1008